Basic & Clinical Medicine ›› 2014, Vol. 34 ›› Issue (3): 418-421.

Previous Articles     Next Articles

Advances of carfilzomib in treatment of relapsed and refractory multiple myeloma


  • Received:2013-08-27 Revised:2013-09-24 Online:2014-03-05 Published:2014-02-27

Abstract: Carfilzomib is a second-generation selective proteasome inhibitor that has been recently used for relapse or refractory multiple myeloma(RRMM). It has been shown to be beneficial in both bortezomib-resistant and bortezomib-naive patients, with a tolerable side effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib.

Key words: Carfilzomib, proteasome inhibitor, multiple myeloma, relapse, refractory, anti-myeloma